David Y Thomas
Overview
Explore the profile of David Y Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mubaid S, Sanchez B, Algehani R, Skopenkova V, Adjibade P, Hall D, et al.
Nucleic Acids Res
. 2024 Feb;
52(7):4002-4020.
PMID: 38321934
Poly(ADP-ribosylation) (PARylation) is a post-translational modification mediated by a subset of ADP-ribosyl transferases (ARTs). Although PARylation-inhibition based therapies are considered as an avenue to combat debilitating diseases such as cancer...
2.
Bergeron J, Thomas D
FEBS J
. 2023 Apr;
290(16):3963-3965.
PMID: 37013685
N-linked glycans are specifically attached to asparagine residues in a N-X-S/T motif of secretory pathway glycoproteins. N-glycosylation of newly synthesized glycoproteins directs their folding via the lectin chaperones calnexin and...
3.
Sato Y, Kim D, Turner M, Luo Y, Zaidi S, Thomas D, et al.
Am J Respir Cell Mol Biol
. 2023 Mar;
69(3):281-294.
PMID: 36952679
CFTR (cystic fibrosis transmembrane conductance regulator) is a tightly regulated anion channel that mediates chloride and bicarbonate conductance in many epithelia and in other tissues, but whether its regulation varies...
4.
Hanrahan J, Abu-Arish A, Wong F, Turner M, Carlile G, Thomas D, et al.
Am J Physiol Cell Physiol
. 2022 Sep;
323(5):C1374-C1392.
PMID: 36121129
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and cigarette smoke is the main risk factor. Detecting its earliest stages and preventing a decline in lung function...
5.
Stevers L, Wolter M, Carlile G, Macdonald D, Richard L, Gielkens F, et al.
Nat Commun
. 2022 Jun;
13(1):3586.
PMID: 35739107
Impaired activity of the chloride channel CFTR is the cause of cystic fibrosis. 14-3-3 proteins have been shown to stabilize CFTR and increase its biogenesis and activity. Here, we report...
6.
Carlile G, Yang Q, Matthes E, Liao J, Birault V, Sneddon H, et al.
Sci Rep
. 2022 Mar;
12(1):4595.
PMID: 35302062
Most cases of cystic fibrosis (CF) are caused by class 2 mutations in the cystic fibrosis transmembrane regulator (CFTR). These proteins preserve some channel function but are retained in the...
7.
Lopes-Pacheco M, Bacalhau M, Ramalho S, Silva I, Ferreira F, Carlile G, et al.
Cells
. 2022 Jan;
11(1).
PMID: 35011698
Although some therapeutic progress has been achieved in developing small molecules that correct F508del-CFTR defects, the mechanism of action (MoA) of these compounds remain poorly elucidated. Here, we investigated the...
8.
Turner M, Sato Y, Thomas D, Abbott-Banner K, Hanrahan J
Cell Physiol Biochem
. 2021 Dec;
55(6):784-804.
PMID: 34936285
Background/aims: Cystic fibrosis transmembrane conductance regulator (CFTR), the anion channel that is defective in cystic fibrosis (CF), is phosphorylated and activated by cAMP-dependent protein kinase (PKA). cAMP levels are downregulated...
9.
Sato Y, Mustafina K, Luo Y, Martini C, Thomas D, Wiseman P, et al.
Sci Rep
. 2021 Dec;
11(1):23256.
PMID: 34853321
There is evidence that the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel is highly expressed at the apical pole of ciliated cells in human bronchial epithelium (HBE), however recent...
10.
Turner M, Abbott-Banner K, Thomas D, Hanrahan J
Pharmacol Ther
. 2021 Mar;
224:107826.
PMID: 33662448
Cystic Fibrosis (CF) lung disease results from mutations in the CFTR anion channel that reduce anion and fluid secretion by airway epithelia. Impaired secretion compromises airway innate defence mechanisms and...